medRxiv preprint doi: https://doi.org/10.1101/2021.05.29.21257899; this version posted June 2, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

COVID Oximetry @home: evaluation of patient outcomes

Michael Boniface[*,1], Daniel Burns[1], Chris Duckworth[1], Franklin Duruiheoma[2], Htwe Armitage[2], Naomi Ratcliffe[2], John Duffy[2], Caroline O'Keeffe[3], Matt Inada-Kim[2]
*m.j.boniface@soton.ac.uk
[1]School of Electronics and Computer Science, University of Southampton, Southampton, SO17 1BJ, UK
[2]Acute Medical Unit, Department of Acute Medicine, Hampshire Hospitals NHS Foundation Trust, Winchester, UK
[3]Clinical Lead for Urgent and Emergency Care – North Hants Clinical Commissioning Group

Abstract

Background: COVID-19 has placed unprecedented demands on hospitals. A clinical service, COVID Oximetry @home (CO@h) was launched in November 2020 to support remote monitoring of COVID-19 patients in the community. Remote monitoring through CO@h aims to identify early patient deterioration and provide timely escalation for cases of silent hypoxia, while reducing the burden on secondary care.

Methods: We conducted a retrospective service evaluation of COVID-19 patients onboarded to CO@h from November 2020 to March 2021 in the North Hampshire (UK) community led service (a collaboration of 15 GP practices, covering a population of 230,000 people). We have compared outcomes for patients admitted to Basingstoke & North Hampshire Hospital who were CO@h patients (COVID-19 patients with monitoring of SpO_2 (n=137)), with non CO@h patients (those directly admitted without being monitored by CO@h (n=633)). Odds Ratio analysis was performed to contrast the likelihood of patient outcomes resulting in 30 day mortality, ICU admission and length of stay greater than 3, 7, 14, and 28 days.

Results: Hospital length of stay was reduced by an average of 6.3 days for CO@h patients (6.9 95% CI [5.6 - 8.1]) in comparison to Non-CO@h (13.2 95% CI [12.2 - 14.1]). The most significant odds ratio effect was on mortality (0.23 95%CI [0.11 - 0.49]), followed by length of stay > 14 days (OR 0.23 95%CI [0.13 - 0.42]), length of stay > 28 days (OR 0.23 95%CI [0.08 - 0.65]), length of stay > 7 days (OR 0.35 95%CI [0.24 - 0.52]), and length of stay > 3 days (OR 0.52 95%CI [0.35 - 0.78]). Mortality and length of stay outcomes were statistically significant. Only 5/137 (3.6%) where admitted to ICU compared with 52/633 (8.2%) for Non-CO@h.

Conclusions: CO@h has demonstrated considerably improved patient outcomes reducing the odds of longer length hospital stays and mortality.

Introduction

The rapidly evolving COVID-19 pandemic has been responsible for 3.4 million deaths worldwide (World Health Organization, 2021) and has placed unprecedented strain on healthcare systems. A significant proportion of patients hospitalised with acute COVID-19 have severe hypoxia (very low blood oxygen saturation) frequently presenting 'silently' (i.e. without breathlessness). Silent hypoxia is an independent indicator of worse patient outcomes (O'Carroll, et al., 2020) (Brouqui, et al., 2021), and delayed presentations of severe COVID-19; often leading to extended hospital stays, higher risk of ICU admission, and higher mortality rates (Vindrola-Padros, et al., 2020).

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2021.05.29.21257899; this version posted June 2, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

UK guidelines recommend that patient acuity should therefore be assessed with the use of pulse oximetry (i.e. monitoring oxygen saturation) when diagnosed with COVID-19 (NHS England, 2020) (Inada-Kim, et al., 2020). A clinical service COVID Oximetry @home (CO@h) was launched November 2020 within a COVID-19 Integrated Care Pathway to support remote monitoring of COVID-19 patients by primary care and timely escalation to secondary care. Remote home monitoring through CO@h have been implemented to 1) maintain NHS capacity, 2) decrease nosocomial COVID-19 transmission, and 3) identify early patient deterioration and provide timely escalation to reduce hospital length of stay, and mortality from silent hypoxia (Stockly, 2020) (Boniface, Zlatev, Guerrero-Luduena, & Armitage, 2020).

In its original definition, a CO@h Service consists of two fundamental components: (1) using a predictive model to identify individual patients in a population who are at high risk of future unplanned hospital admission; and (2) offering these people a period of intensive, multidisciplinary, case management at home using the systems, staffing and daily routine (Lewis et al., 2006) (Lewis, et al., 2013). Patients are referred by clinical services responsible for operating CO@h services then triaged prior to onboarding for remote monitoring to ensure that the CO@h offers an appropriate level of care.



Figure 1: Primary care assessment centre and COVID Oximetry @home service deployed supporting community patient monitoring as defined by North Hampshire Integrated Care System.

Even though the CO@h service is virtual, it is integrated into a care partnership with physical care for patient assessment (e.g. COVID-19 testing and initial observations) when deemed clinically appropriate. A schematic of the Integrated Care Partnership for North Hampshire is shown in Figure 1, highlighting the important relationship between physical and virtual services in the overall delivery of care.

This report outlines a quality improvement (QI) initiative to implement CO@h service in North Hampshire and retrospectively evaluate their efficacy. Through adoption of the Plan-Do-Study-Act (PDSA) framework and using evidence-based practice, the CO@h services were continually improved as a rapid response to the evolving pandemic. Evidence-based practice was enabled by close communication between professional analysts, who provided data insight, and healthcare

medRxiv preprint doi: https://doi.org/10.1101/2021.05.29.21257899; this version posted June 2, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

professionals, who provided operational insight. CO@h went live in November 2020 although it should be noted that some pilot services were operational in North Hampshire during the 1st wave of the pandemic from April 2020 to June 2020. The data relating to CO@h pilots during the 1st wave period was not available for analysis. In this report we aim to disseminate the effectiveness of the CO@h service implemented in the Integrated Care Partnership of North Hampshire. To our knowledge, this is the first QI initiative directly reporting outcomes for COVID-19 patients treated virtually for an NHS Trust. Our findings will be of interest to healthcare organisations looking to implement further CO@h services as a response to the ongoing pandemic.

Methods

Patient Population

All patients with suspected COVID-19 admitted to North Hants CO@h or Basingstoke and North Hants Hospital between 1 November 2020 to 31 March 2021 were eligible for inclusion. CO@h patients were then linked to their subsequent hospital admissions. Confirmed COVID-19 cases were then identified from these suspected cases by requiring at least one SARS-CoV-2 positive test associated with the admission.



Figure 2: Patient cohort selection showing CO@h intervention group and Non-CO@h control group (those patients not being treated by the CO@h service)

We separated our cohort into an intervention group, where patients had at least one referral to the CO@h service, and a control group, where patients have not had such a referral. There was a total of 1496 patients, with 783 patients in the intervention group and 713 patients in the control group. To evaluate the outcomes between comparable groups, we required that each patient in the intervention group had at least one hospital admission via the emergency department. We therefore excluded patients in the intervention group who returned a negative COVID test result following referral to CO@h (n=35) and those whose outcomes did not result in escalation to hospital (n=611), leaving 137 CO@h patients that were escalated to hospital.

For the control group we excluded COVID-19 patients (n=80) admitted from hospital locations other than the emergency department to reduce confounding factors between the intervention and control groups: patients in this group may have already been admitted to hospital with complex ongoing acute

medRxiv preprint doi: https://doi.org/10.1101/2021.05.29.21257899; this version posted June 2, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

care needs in addition to COVID-19 resulting in an increased likelihood for negative outcomes, such as longer length of stay and mortality. This left 633 patients in the Non-CO@h control group, of which 55 patients were readmitted to hospital within 30 days of first admission. For readmissions an episode of care was created aggregating length of stay over multiple admissions and where the patient outcome was deemed to be the outcome from the last admission event.

Target Outcome

We evaluated the CO@h service using a comparison of increasingly acute outcomes associated with COVID-19 patient trajectory for those with a positive COVID-19 test who required admission to hospital. We considered the following outcomes: 30 day mortality, ICU admission, and whether the length of stay in hospital was above 3 days, 7 days, 14 days, or 28 days. We identified a death through hospital medical records. We identified ICU admissions through a specific electronic patient record flag. The length of stay was computed from the point of hospital admission to discharge.

Data Collection

We have linked data from primary care systems operated by CO@h with secondary care systems operated by Hampshire Hospitals NHS Foundation Trust (HHFT) to create a database supporting analysis of the full trajectory of COVID episodes. The linking included CO@h service and hospital admission records.

To ensure that the data used is of a satisfactory quality, we subsequently excluded admissions that did not meet the following criteria: for each admission record, we required that admission date must be equal to or before the discharge date; the discharge date and patient outcome must be recorded; and that any duplicate records were removed. There were 2 hospital admission records with a discharge date before the corresponding admission date, and 11 admissions without a discharge date or outcome. There were 2 instances of duplicates: 1 duplicate set of CO@h referral records, and 1 duplicate set of hospital admission records.

The dataset also contains some hospital admission records for which the date of admission is prior to discharge from a CO@h service. In some cases, patients admitted to hospital were not discharged from CO@h immediately. If the hospital admission was likely to only be less than 24hrs (i.e., Same Day Emergency Care), patients would continue intervention by CO@h seamlessly as they left hospital. If hospital admission was longer than 24 hours, patients were discharged from CO@h, and in some cases referred back to CO@h following hospital discharge. Patients were also given advice to contact 999, or another service based on their self-submitted readings. In some cases, the patient would then be conveyed and admitted to hospital ahead of discharge from the CO@h service. In all cases, we include those patients within our intervention group as they have received the CO@h intervention.

Data Analysis

For each outcome, we have produced contingency tables and calculated the odds ratio with 95% confidence intervals. We have calculated the empirical cumulative distribution function for length of stay in the intervention and control groups, in addition to their smoothed distribution functions (calculated by kernel density estimate with a Gaussian kernel restricted to positive values). Analysis was performed in Python v3.9.4 (using pandas, seaborn, statsmodels).

Data Governance

medRxiv preprint doi: https://doi.org/10.1101/2021.05.29.21257899; this version posted June 2, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

This service evaluation did not require ethics approval. The study was however evaluated by the University of Southampton Ethics Committee (REF ERGO/61242) and approved as a service evaluation following Data Protection Impact Assessment and establishment of Data Sharing Agreements. NHS England and NHS Improvement have been given legal notice by the Secretary of State for Health and Social Care to support the processing and sharing of information to help the COVID-19 response under Health Service Control of Patient Information Regulations 2002 (COPI). This is to ensure that confidential patient information can be used and shared appropriately and lawfully for purposes related to the COVID-19 response. Data were extracted from medical records by clinicians providing care for the patients and an anonymised extract of the data were provided to the team at the University of Southampton.

Data Accessibility

Due to information governance concerns, the data will not be made public. However, it may be made accessible via reasonable request to the corresponding author.

Results

The North Hants CO@h service treated 783 patients of which 137 patients were subsequently escalated and admitted to hospital. The Basingstoke and North Hants hospital had a further 692 admissions (633 individual patients) directly via the emergency department who were not treated by the CO@h service.



Figure 3: Monthly COVID-19 referrals for monitoring by CO@h service (blue) and total hospital admissions (orange) from November 2020 to March 2021. Hospital admissions include CO@h referrals escalated and admitted to hospital.

The uptake of the CO@h service is shown in Figure 3. The ratio of CO@h referrals to the number of hospital admissions increased consistently throughout the period, with a ratio of 30/113 (1:4) during November 2020, to 85/21 (4:1) during March 2021. The uptake reached a maximum of 363 referrals

medRxiv preprint doi: https://doi.org/10.1101/2021.05.29.21257899; this version posted June 2, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

during January 2021 coinciding with the increase in COVID-19 prevalence during that period. Table 1 shows the age and gender demographics for patients in the intervention and control groups as ascertained from by medical records.

Characteristic	**CO@h**	**Non-CO@h**
No.	137	633
Age Group		
0-19	0 (0)	9 (1.3)
20-45	18 (13.1)	93 (13.4)
46-65	50 (36.5)	167 (24.1)
66-85	52 (38)	263 (38)
85+	17 (12.4)	101 (14.6)
Gender		
Female	70 (51.1)	289 (41.8)
Male	67 (48.9)	344 (49.7)

Table 1. Patients basic demographics with positive SARS-CoV-2 test result treated by CO@h service in comparison to those admitted directly to hospital (Non-CO@h)

Distributions representing the length of stay for both the intervention and control groups are shown in Figure 3. The 80th percentile length of stay for the intervention group was 9 days, 10 days shorter than the 21 days for the control group. The mean length of stay was 6.9 days (95% CI 5.6 - 8.1 days) in the intervention group, and 13.2 days (95% CI 12.2 – 14.1 days) in the control group.



Figure 4: Hospital length of stay distributions for our intervention (CO@h; blue) and control cohorts (Non-CO@h; orange). (Left) cumulative distribution for length of stay with 80th percentile length of stay shown as vertical lines for each period. (Right) kernel density estimate for hospital length of stay

In Table 2, we summarise the odds ratios for each outcome. The most significant odds ratio effect was on mortality (0.23 95%CI [0.11 - 0.49]), followed by length of stay > 14 days (OR 0.23 95%CI [0.13 - 0.42]), length of stay > 28 days (OR 0.23 95%CI [0.08 - 0.65]), length of stay > 7 days (OR 0.35 95%CI [0.24 - 0.52]), and length of stay > 3 days (OR 0.52 95%CI [0.35 - 0.78]). Mortality and length of stay outcomes were statistically significant. For ICU admission, we observed no difference between CO@h and Non-CO@h (OR 0.42 95%CI [0.17 - 1.08]) because we did not reach statistical significance. The

medRxiv preprint doi: https://doi.org/10.1101/2021.05.29.21257899; this version posted June 2, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

CO@h population included 5/137 (3.6%) where admitted to ICU in comparison to 52/633 (8.2%) for Non-CO@h.

Outcome	**Length of Stay**				**ICU Admission**	**Mortality**
	> 3 days	> 7 days	> 14 days	> 28 days		
CO@h Odds Ratio (n=770)	0.52 95%CI [0.35 - 0.78]	0.35 95%CI [0.24 - 0.52]	0.23 95%CI [0.13 - 0.42]	0.23 95%CI [0.08 - 0.65]	0.42 95%CI [0.17 - 1.08]	0.23 95%CI [0.11 - 0.49]

Table 2: Odds ratio for CO@h compared to Non-CO@h patients for length of stay, ICU admission and mortality outcomes

Admissions with 30 day mortality outcome for the CO@h were 8/137 (5.8%), compared with 130/633 (20.5%) for Non-CO@h: 71.7% reduction. No patients were readmitted to hospital within 30 days of hospital admission for those admitted from CO@h, compared with 55/633 (8.7%) for Non-CO@h.

Discussion

The CO@h initiative was implemented nationally to protect patients by improving early recognition of deterioration in COVID-19 and to protect the healthcare system from being overwhelmed with inappropriate admissions. The CO@h service was universally implemented across England (by Feb 2021) over a period of 3 months.

In this QI initiative we focussed on evaluating the efficacy of CO@h by retrospectively evaluating COVID-19 patient outcomes for those admitted to CO@h in North Hants Primary Care Network and subsequently being admitted to hospital. The initiative achieved its aim with statistically significant reductions in length of stay, ICU admission, and mortality rate for patients admitted to hospital via the CO@h pathway relative to direct hospital admission.

Patients hospitalised with acute COVID-19 are at severe risk of hypoxia, which can commonly present without breathlessness (Greenhalgh, et al., 2021). The benefits of identifying hypoxia early are clear (Knight & al., 2020), however to our knowledge, this QI service evaluation is the first to demonstrate that CO@h has resulted in improved patient outcomes for an NHS trust (i.e., mortality, ICU admission and length of stay). This CO@h service was implemented as part of the national framework (NHS England, 2020) and therefore these findings should be of interest to future CO@h operations in response to the pandemic. CO@h services have now been provisioned internationally, for example, StepOne have applied the CO@h model to support intervention of COVID patients across 16 states in India (George Institute, 2021).

COVID-19 is endemic worldwide, and hence, there is an urgent need for optimised early identification of patient deterioration for patients at home. As healthcare systems aim to restore elective activity, the backlog of non-COVID patients requiring intervention is stark. In England, the British Medical Association estimates there were 3.37 million fewer elective procedures and 21.4 million fewer outpatient attendances between April 2020 and March 2021 (Association, 2021).

The COVID-19 pandemic has generated research into effective and streamlined patient care which has ramifications beyond the context of the pandemic. CO@h is one aspect of the nationally led programme NHS @home; which aims to maximise the use of technology to support more people to better self-manage their health and care at home (NHS England, NHS @home, 2021). With access to more timely preventative care, patient burden on both primary and emergency care can be reduced while providing patients more personalised intervention. In particular, home pulse oximetry has long

medRxiv preprint doi: https://doi.org/10.1101/2021.05.29.21257899; this version posted June 2, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

been used in primary care settings as a cost-effective approach to monitor chronic lung conditions and heart disease (Plüddemann, Thompson, Heneghan, & Price, 2011), and there is a growing evidence base for the model's effectiveness and safety in COVID-19 (Vindrola-Padros, et al., 2020) (Inada-Kim, et al., 2020) (Boniface, Zlatev, Guerrero-Luduena, & Armitage, 2020) (Greenhalgh, et al., 2021) (Nunan, et al., 2020). Further prospective studies are required to understand how remote monitoring can be implemented in wider contexts, potentially focussed on high risk patients with significant co-morbidities.

These findings must be understood in light of their limitations. CO@h was rapidly developed in response to the pandemic, and as a result, the improvement cycles were conducted at pace. PDSA quality improvement was conducted using evidence-based practice, where insights were provided by data professionals to clinicians. A multi-disciplinary team of healthcare professionals, QI personnel, and data scientists met frequently to discuss patient care, and CO@h efficacy. Operational improvements were implemented through these discussions to deliver continual improvement especially procedures relating to integrated services between conveyance, CO@h and hospitals. Formally, the distinct improvement cycles were as follows: (1) CO@h service pilots (1st wave of the pandemic: March 2020 to July 2020) including community COVID-19 assessment centres implemented without remote monitoring beyond paper diaries and phone, treating n=1600 suspected-COVID patients and escalating n=105 to hospital; and support by hospital Same Day Emergency Care and care homes telemedicine services (2) NHS Trust-wide implementation of CO@h (2nd wave of the pandemic: November 2020 to March 2021) with efficacy evaluation presented here. Finally, this service evaluation is for an integrated community care pathway and a single hospital trust, therefore generalisation is limited by population size and clinical setting.

Conclusion

COVID Oximetry @home (CO@h) has demonstrated significantly improved patient survival, while increasing hospital capacity. To our knowledge, this is the first QI report concerning the efficacy of CO@h service and evaluation of mortality, ICU admission, and length of stay benefits for an NHS Hospital Trust. COVID-19 patients admitted to the CO@h service have been found to have significantly reduced odds of longer length hospital stays, and mortality. These findings demonstrate that, despite the studies limitations, CO@h should be considered nationally and internationally in response to the ongoing pandemic and that larger evaluations of efficacy and quality should be undertaken.

Acknowledgements

We thank Claire Parker from Hampshire, Southampton & Isle of Wight Clinical Commissioning Group for their support during the specification, delivery, and evaluation of CO@h. We extend our special thanks to the CO@h Clinical Team who cared for patients and collated data including Alison Hullah (Lead Advanced Nurse Practitioner), Roisin Howell (Lead Advanced Nurse Practitioner) and Giselle Beaumont (Care Coordinator). This report received funding from the NHSX RECOxCARE (Remote oximetry in community care for COVID-19 patients) project and from NHS England to support data collection. The views expressed in this publication are those of the author(s) and not necessarily those of the funders.

References

Association, B. M. (2021). *Pressure points in the NHS.* Retrieved from https://www.bma.org.uk/advice-and-support/nhs-delivery-and-workforce/pressures/pressure-points-in-the-nhs

medRxiv preprint doi: https://doi.org/10.1101/2021.05.29.21257899; this version posted June 2, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Boniface, M., Zlatev, Z., Guerrero-Luduena, R., & Armitage, H. (2020). *An Evidence-Based Approach to Quality Improvement for COVIDoximetry@home.* NIHR Applied Research Collaboration (ARC) Wessex. Available: https://eprints.soton.ac.uk/445388/1/RECOxCARE_Evidence_Based_QI_CWD_v1.0_final.pdf .

Brouqui, P., Amrane, S., Million, M., Cortaredona, S., Parola, P., Lagier, J.-C., & Raoult, D. (2021). Asymptomatic hypoxia in COVID-19 is associated with poor outcome. *Int J Infect Dis., 102*, 233-238.

George Institute. (2021). *Home-based COVID care through teleconsultation services can prevent overcrowding in hospitals*. Retrieved from https://www.georgeinstitute.org.in/news/home-based-covid-care-through-teleconsultation-services-can-prevent-overcrowding-in-hospitals

Greenhalgh, T., Knight, M., Inada-Kim, M., Fulop, N. J., Leach, J., & Vindrola-Padros, C. (2021). Remote management of covid-19 using home pulse oximetry and virtual ward support. *BMJ, 372*, n677.

Inada-Kim, M., Chmiel, F. P., Boniface, M. J., Pocock, H., Black, J. J., & Deakin, C. D. (2020). Validation of home oxygen saturations as a marker of clinical deterioration in patients with suspected COVID-19. *medRxiv Availiable: https://doi.org/10.1101/2020.11.06.20225938*.

Knight, S. R., & al., e. (2020). Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. *BMJ, 370*, m3339.

Lewis, G. (2006). *Case study: virtual wards at Croydon primary care trust. London, UK: The King's Fund.* Retrieved from www.kingsfund.org.uk/sites/files/kf/field/field_document/PARR-croydon pct case study.pdf

Lewis, G., Vaithianathan, R., Wright, L., Brice, M. R., Lovell, P., Rankin, S., & Bardsley, M. (2013). Integrating care for high-risk patients in England using the virtual ward model: lessons in the process of care integration from three case sites. *International journal of integrated care, 13*, e046.

NHS England. (2020, June 11). Pulse oximetry to detect early deterioration of patients with COVID-19 in primary and community care settings. Retrieved from www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/06/C0445-remote-monitoring-in-primary-care-jan-2021-v1.1.pdf

NHS England. (2021). *NHS @home*. Retrieved from https://www.england.nhs.uk/nhs-at-home/

Nunan, J., Clarke, D., Malakouti, A., Tannetta, D., Calthrop, A., Xu, X., . . . Walden, A. (2020). Triage Into the Community for COVID-19 (TICC-19) Patients Pathway - service evaluation of the virtual monitoring of patients with COVID pneumonia. *Acute Medicine Journal, 19*, 183-91.

O'Carroll, O., MacCann, R., O'Reilly, A., Dunican, E. M., Feeney, E. R., Ryan, S., . . . McCarthy, C. (2020). Remote monitoring of oxygen saturation in individuals with COVID-19 pneumonia. *European Respiratory Journal, 56*(2).

Plüddemann, A., Thompson, M., Heneghan, C., & Price, C. (2011). Pulse oximetry in primary care: primary care diagnostic technology update. *The British journal of general practice : the journal of the Royal College of General Practitioners, 61*, 358-9.

medRxiv preprint doi: https://doi.org/10.1101/2021.05.29.21257899; this version posted June 2, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Stockly, S. (2020). *RCGP paper on Virtual Wards, Silent Hypoxia and improving COVID.* Retrieved from https://elearning.rcgp.org.uk/pluginfile.php/149506/mod_page/content/88/Virtual%20wards%2C%20silent%20hypoxia%20and%20improving%20COVID%20outcomes_formatted_28.10.20.pdf

Vindrola-Padros, C., Singh, K. E., Sidhu, M. S., Georghiou, T., Sherlaw-Johnson, C., Tomini, S., . . . Fulop, N. J. (2020). Remote home monitoring (virtual wards) during the COVID-19 pandemic: a systematic review. *medRxiv, Available: https://www.medrxiv.org/content/early/2020/10/12/2020.10.07.20208587*.

World Health Organization. (2021). *WHO Coronavirus (COVID-19) Dashboard*. Retrieved from https://covid19.who.int/